Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "Rocuronium Bromide" patented technology

The bromide salt form of rocuronium, an intermediate-acting quaternary aminosteroid with muscle relaxant property. Rocuronium bromide competitively binds to the nicotinic receptor at the motor end plate, and antagonizes acetylcholine binding, which results in skeletal muscle relaxation and paralysis.

Synthetic method of bromamines muscle relaxant

The invention provides a bromide type muscle relaxant, which mainly comprises a method for synthesizing rocuronium bromide, vecuronium bromide, pancuronium bromide and pipecuronium bromide , and is mainly characterized by adopting a ketene as an acylating agent during the process of transforming 5Alpha-androstane -2-alkene-17-alkone to 17-acetoxyl group-5Alpha- androstane-2, and 16-diene, adopting a stress kettle as a reactor when realizing the step of ring-opening and condensation of the 2 Alpha and 3 Alpha-epoxy compound, and adding a solid catalyst and a desiccant in the last step of operation of rocuronium bromide to greatly improve the reaction yield and the quality of products. The technology provided by the invention can shorten the synthesis time of the bromide type muscle relaxant, simplify the operation steps, improve the quality of products and reduce the production cost.
Owner:王加旺

Stable rocuronium bromide composition for injection

The invention provides a stable rocuronium bromide composition for vein, which contains rocuronium bromide with treating effective dose, EDTA-2Na-Ca or EDTA-2Na and a pH value buffer system. The EDTA-2Na-Ca or the EDTA-2Na delays the hydrolysis of a rocuronium bromide 17-bit ester bond of the composition in the processes of preparation and storage; and on one hand, medicine liquid can resist the high temperature in the processes of hot press and sterilization, on the other hand, the content of rocuronium bromide deacetyl impurities in the composition in the process of storage is reduced. The invention also provides a reasonable method for preparing the medicine liquid, which can reduce the generation of the rocuronium bromide hydrolysis impurities in the process of preparation. The reduction of the rocuronium bromide hydrolysis impurities improves the quality controllability of the composition and ensures the safety and effectiveness of clinical use.
Owner:尹双保 +2

Novel method for preparing rocuronium bromide

InactiveCN107312055AAvoid Chemoselectivity ProblemsAvoid it happening againSteroidsEpoxyMorpholine
The invention relates to a novel method for preparing rocuronium bromide 1-[17beta-acetoxyl-3alpha-hydroxyl-2beta-(4-morpholinyl)-androstane-16beta-yl]-1-(2-propenyl) pyrrole bromide, the problem of chemoselectivity of pyrrolidine open epoxy in an original line is solved, generation of byproducts is avoided, reaction yield is greatly improved, the production cost is reduced, column chromatography separation is avoided, and aftertreatment purification is implemented easily.
Owner:JIANGSU QINGJIANG PHARMA

Method for preparing rocuronium crystalline hydrate

The invention relates to a preparation method of bulk drugs, in particular to a preparation method of rocuronium bromide crystalline hydrate, which comprises the following steps of: preparing the rocuronium bromide aqueous solution with 2-15 percent of weight volume percent concentration, freezing the aqueous solution to ice under -50-30 DEG C, decompressing and heating up to 30-50 DEG C under vacuum state, keeping 10-20 hours of temperature-rise period and preserving heat for 10-30 hours in vacuum at the temperature. The rocuronium bromide crystalline hydrate prepared by the method enhances the stability of the rocuronium bromide bulk drugs, improves the particle exterior of the rocuronium bromide and effectively reduces the excessive organic residue of the rocuronium bromide bulk drugs.
Owner:重庆人本药物研发有限责任公司

Preparation method of high-purity rocuronium bromide

ActiveCN108570090ALow solvent residueLow in 3-bromopropeneSteroidsAqueous acetoneSolvent
The invention provides a preparation method of high-purity rocuronium bromide. The preparation method comprises the steps of enabling a rocuronium bromide crude product to be dissolved in acetone water solution, filtering, vacuum-concentrating, adding normal heptane for homogenizing, pulping and the like. The provided preparation method of the high-purity rocuronium bromide has many advantages ofextremely low solvent residual quantity, extremely high HPLC purity, extremely low related substance content, extremely high stability and the like.
Owner:江苏盈科生物制药有限公司

Method for purifying rocuronium bromide

Provided is a method for purifying rocuronium bromide, which comprises: formulating crude rocuronium bromide to be purified into an aqueous solution, distilling off excess residue solvents at reduced pressure, absorbing by adding active carbon or silica gel, then filtrating, quick freezing the filtrate into ice, and then lyophilizing to obtain rocuronium bromide.
Owner:ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD

Method for preparing rocuronium bromide midbody compound crystal

The invention discloses a method for preparing rocuronium bromide midbody compound crystal, which is characterized in that compound 2beta-(4-morpholinyl)-16beta-(1-pyrrolidyl)-5alpha-androstane-3alpha, 17beta-glycol is adopted as raw material to be proceeded with acylation reaction and then to be refined to obtain crystal powder compound 2beta-(4 - morpholinyl)-16beta-(1 - pyrrolidinyl)-5alpha-Androstane-3alpha, 17beta-diol - 2 acetate with high purity. With the method, the fallow crystal powder compound with high purity can be prepared, and conditions are created for synthesizing high-quality rocuronium bromide.
Owner:ZHEJIANG XIANJU PHARMA

Preparation method for rocuronium bromide key intermediate 2alpha, 3alpha-epoxy-16beta-(1-pyrrolidyl)-5alpha- androstane-17 hydroxy

InactiveCN102633858AStereoselectiveGood stereoselectivitySteroidsAndrostanePyrrole
The invention belongs to the field of pharmaceutical chemistry synthesis, and relates to a preparation method for a key intermediate 2alpha, 3alpha-epoxy-16beta-(1-pyrrolidyl)-5alpha- androstane-17 hydroxy of rocuronium bromide of steroid muscle relaxant, which includes the steps: leading inexpensive and available 5alpha-androstane-2-alkene-17 ketone and isopropenyl acetate to undergo ester exchange to generate cresyl violet acetate, oxidizing the cresyl violet acetate by the meta-chloroperoxybenzoic acid to obtain an epoxy compound, carrying out an open-loop substitution reaction between the meta-chloroperoxybenzoic acid and pyrrolidine under the alkaline condition, and reducing via sodium borohydride so that the rocuronium bromide key intermediate 2alpha, 3alpha-epoxy-16beta-(1-pyrrolidyl)-5alpha-androstane-17 hydroxy is prepared. An ester group with large steric hindrance is generated at the 17th position when the 5alpha-androstane-2-alkene-17 ketone and the isopropenyl acetate undergo ester exchange in the process to lead stereoscopic steric hindrance of a whole steroid ring to be large, so that attack on the lower portion of the steroid ring can be performed when epoxidation is carried out, and further stereoselectivity is high when an epoxide is formed, and then a beta configuration can be directly formed when the pyrrolidine is used for substitution. The synthesis method is good in stereoselectivity.
Owner:LIANYUNGANG GUIKE PHARMA

Rocuronium bromide enantiomeric impurity, or salt thereof and method for preparing rocuronium bromide enantiomeric impurity or salt

The invention discloses a rocuronium bromide enantiomeric impurity, a salt, a solvate, an enantiomer or a diastereoisomer of the rocuronium bromide enantiomeric impurity and a method for preparing the same. The rocuronium bromide enantiomeric impurity is shown as a formula V. An R1 and an R2 in the formula V are independently selected from H and acetyl; an R3 is selected from N-pyrrolidyl and N-allyl pyrrolidyl. The invention further provides application of the rocuronium bromide enantiomeric impurity to detecting the quality of rocuronium bromide intermediates, crude drugs or preparations. The rocuronium bromide enantiomeric impurity, the salt, the solvate, the enantiomer or the diastereoisomer, the method and the application have the advantages that gaps in the aspect of research on rocuronium bromide impurities can be filled, and foundations and bases can be provided for controlling the quality of rocuronium bromide materials or drugs.
Owner:CHENGDU SINO STRONG PHARMA

Water-soluble cucurbit [8] urea sulfonate derivative as well as preparation method and application thereof

ActiveCN113563352AExcellent relaxationExcellent effect Reversal of relaxationOrganic active ingredientsOrganic chemistrySulfonateAntagonism
The invention belongs to the technical field of biological medicine, and relates to a water-soluble cucurbit [8] urea sulfonate derivative serving as a neuromuscular blocker antagonist as well as a preparation method and application thereof. The water-soluble cucurbit [8] urea sulfonate derivative is obtained by taking cucurbit [8] urea as a raw material and introducing a water-soluble side chain group through a chemical reaction; a hydrophobic cavity of the water-soluble cucurbit [8] urea sulfonate derivative can be combined with neuromuscular blockers including cis-asatracurium besylate, rocuronium bromide, vecuronium bromide and pantocuronium bromide in a water phase through interaction of hydrophobic agents, so that antagonism is achieved. Experiments show that the water-soluble cucurbit [8] uril derivative can efficiently antagonize various neuromuscular blockers in a living body, is high in universality and low in biotoxicity, and is an ideal neuromuscular blocker antagonist.
Owner:FUDAN UNIV

Preparation method of rocuronium bromide intermediate 5alpha-sterane-2-ene-17-one

The invention discloses a preparation method of a rocuronium bromide intermediate 5alpha-sterane-2-ene-17-one. The specific steps include: sequentially adding epiandrosterone TS, a solvent and a phasetransfer catalyst into a reaction bottle, performing heating to a reaction temperature of 90-120DEG C, carrying out stirring reaction, and conducting post-treatment purification to obtain the 5alpha-sterane-2-ene-17-one. The method provided by the invention greatly shortens the reaction time, reduces byproducts, enhances the yield, reduces three wastes, lowers the production cost, is suitable forindustrial production, and has obvious social and economic benefits.
Owner:ZENJI RES LAB

Preparation method of rocuronium bromide intermediate

The invention belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of a rocuronium bromide intermediate. The preparation method comprises the following steps: by taking epiandrosterone as shown in a formula I as a raw material, carrying out dehydration reaction under the catalysis of an Eaton reagent, and then washing, extracting and concentrating to obtain the rocuronium bromide intermediate (5alpha-androstane-2-ene-17-ketone). According to the preparation method, the reaction temperature is reduced to 40 DEG C, byproducts of high-temperature reaction are reduced, white-like solids can be obtained by simply washing, extracting and concentrating reaction liquid, and main product loss caused when the byproducts are removed through recrystallization is reduced. And the process is simpler, the yield is lower, and the emission of three wastes is less.
Owner:福安药业集团重庆博圣制药有限公司

Inhalation preparation for treating asthma

The invention relates to an inhalation preparation for treating asthma. The inhalation preparation is prepared by taking one of otilonium bromide, oxyphenonium bromide, pipecuronium bromide, rocuronium bromide, pancuronium bromide, pinaverium bromide and vecuronium bromide as active ingredient and mixing pharmaceutical-accepted auxiliary materials. The inhalation preparation includes but is not limited to dry powder inhaler, aerosol and spray.
Owner:FOSHAN YIBAOSHENG PHARMA CO LTD

New compound for muscle relaxation antagonism

The invention discloses a new compound for muscle relaxation antagonism. The new compounds of theta type, beta type, gamma type, lambda type, kappa type, nu type, tau type, omega type, upsilon type and the like of sugammadex sodium have less hygroscopicity and better storage stability, are more beneficial to quality control of medicines and preparations and the like, and are suitable for preparingspecific binding neuromuscular block antagonists. And the compound can be applied to drugs for antagonizing treatment or prevention of neuromuscular block induced by rocuronium bromide or vecuroniumbromide and the like.
Owner:刘力

Rocuronium bromide crystal form

The invention discloses a crystal form A of rocuronium bromide. Cu-Kalpha radiation is used; an X-ray powder diffraction pattern expressed by a 2theta angle has characteristic diffraction peaks at positions of 8.0 + / - 0.2 degrees, 11.1 + / - 0.2 degrees, 15.4 + / - 0.2 degrees, 15.9 + / - 0.2 degrees, 17.1 + / - 0.2 degrees, 18.2 + / - 0.2 degrees, 19.0 + / - 0.2 degrees, 19.6 + / - 0.2 degrees, 20.2 + / - 0.2 degrees, 22.0 + / - 0.2 degrees, 22.8 + / - 0.2 degrees and 25.4 + / - 0.2 degrees. The preparation method of the rocuronium bromide crystal form is simple, and the rocuronium bromide crystal form has good stability and is more beneficial to production, storage and transportation.
Owner:CHENGDU SINO STRONG PHARMA

Preparation method of rocuronium bromide starting material (LK-7) single crystal

The invention belongs to the technical field of raw material medicine preparation, and particularly relates to a single crystal culture method for a rocuronium bromide starting raw material (LK-7). According to the technical scheme, the method comprises the following steps: firstly, dissolving a certain amount of LK-7 solid in a proper amount of organic solvent at a certain temperature to obtain an LK-7 solution with a certain concentration, and meanwhile, ensuring that the obtained solution is clear and transparent without any macroscopic particles; and culturing the LK-7 single crystal by adopting a volatile solvent method. The invention provides a culture method of an LK-7 single crystal, and provides a scientific method for quality control of an initial bulk drug LK-7, especially for confirmation of an absolute configuration of a chiral center.
Owner:北京满格医药科技有限公司 +1

Method for detecting rocuronium bromide intermediate and impurities

The invention provides a method for detecting a rocuronium bromide intermediate and impurities, which adopts a high performance liquid chromatography to detect and analyze the rocuronium bromide intermediate, an impurity 1, an impurity 2, an impurity 3 and an impurity 4. According to the method, known impurities can be accurately detected, the main peak of the intermediate and the peak of the known impurities can be effectively separated, and the method is a brand-new detection and analysis method beneficial to quality control of the rocuronium bromide intermediate. The method is high in sensitivity, wide in linear range, good in specificity and repeatability and easy and convenient to operate.
Owner:JIANGSU LONG HEALTHCARE

Rocuronium bromide injection preparation and preparation method thereof

The invention discloses a rocuronium bromide injection preparation. The pH (Potential of Hydrogen) value of the rocuronium bromide injection preparation is between 2.0 and 2.2 or between 3.8 and 4.2; comprising main medicines and auxiliary materials, wherein the content of the main drug in the rocuronium bromide injection preparation is 10 mg / mL; the main drug is rocuronium bromide; the auxiliary material is a pH regulator. The rocuronium bromide injection prepared by the preparation method provided by the invention has better stability, and can still meet the standard of the product in Chinese pharmacopoeia after being stored for 36 months at normal temperature.
Owner:杭州泓友医药科技有限公司

Preparation method of rocuronium bromide

The invention provides a preparation method of rocuronium bromide. The preparation method comprises the following steps: step 1, reacting a raw material compound I with acetyl chloride to obtain a compound II; 2, dropwise adding a hydrochloric acid solution into the compound II obtained in the step 1 to carry out a hydrolysis reaction, performing standing for layering, removing part of an organiclayer, adjusting the pH value of the residual reaction solution to 7-9 by using a sodium carbonate aqueous solution, separating out an organic phase, and treating to obtain a compound III; 3, adding dichloromethane, anhydrous magnesium sulfate and alkaline aluminum oxide into the compound III and allyl bromide, carrying out a quaternization reaction under the nitrogen flow, filtering under the protection of nitrogen after the reaction is completed, concentrating a filtrate to obtain a concentrate, pulping the concentrate by using a dichloromethane-methyl tert-butyl ether-ethyl acetate system,separating out solids, and carrying out freeze drying to obtain a rocuronium bromide pure product. The purity of the prepared bulk drug product is greater than or equal to 99.8% (according to a USP40correction result), the maximum impurity content is less than or equal to 0.1% (according to the USP40 correction result), and the solvent residue sum is less than or equal to 0.5%.
Owner:武汉华龙生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products